Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00207948 · ClinicalTrials.gov registry record
Optimizing Antiretroviral Therapy in HIV-Infected Children and Adolescents
A clinical trial, sponsored by Children's National Research Institute.
- Terminated
- Registry status
- 4
- Enrollment target
NCT00207948: Clinical Trial study, sponsored by Children's National Research Institute.
NCT00207948 is a clinical trial that was terminated before completion, run by Children's National Research Institute. The registered enrollment target is 4 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00207948 was terminated before completion, sponsored by Children's National Research Institute.
- TERMINATED
- Registry status
- 4 participants
- Enrollment target
Study Summary
This was a feasibility study aimed at elevating protease inhibitors (PI) dosage as a part of active antiretroviral therapy (HAART). After the pharmacokinetics for the currently prescribed PI were determined,patients with a vIQ\<1 were eligible for a 50% dose increase for an 8 week time frame after which their vIQ would be reassessed to determine if increasing their PI dosage thereby increasing the bioavaiability would reduce their viral load.
Primary Outcome
vIQ would be reassessed to determine if increasing their PI dosage thereby increasing the bioavaiability would reduce their viral load.
Interventions
- DRUG Dose adjustment of Kaletra
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2004-11 |
| Est. Completion | 2009-07 |
Why NCT00207948 stopped before completion
NCT00207948 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 4 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Dose adjustment of Kaletra is the first listed.
NCT00207948 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00207948 about?
NCT00207948 is a clinical study titled "Optimizing Antiretroviral Therapy in HIV-Infected Children and Adolescents". This was a feasibility study aimed at elevating protease inhibitors (PI) dosage as a part of active antiretroviral therapy (HAART). After the pharmacokinetics for the currently prescribed PI were determined,patients with a vIQ\<1 were eligible for a 50% dose increase for an 8 week time frame after w...
What is the current status of trial NCT00207948?
This trial is currently terminated. The enrollment target is 4 participants. The study started on 2004-11. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00207948?
The interventions under investigation include: Dose adjustment of Kaletra (DRUG).
Who is sponsoring clinical trial NCT00207948?
This trial is sponsored by Children's National Research Institute, which has 92 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia